A Phase IV Clinical Trial of Patients with Solid Tumors Receiving Lenograstim as Primary Prophylaxis for Chemotherapy-Induced Neutropenia, in a Docetaxel-Based Regimen
Table 1
Patient and cancer baseline characteristics.
Baseline characteristic
Number of patients (%)
Sex
Male
49 (12)
Female
345 (88)
Age (years)
Median
54
Range
26–88
ECOG performance status
Grade 0
232 (58.9)
Grade 1
128 (32.5)
Grade 2
11 (2.8)
Grade 3
1 (0.3)
Grade 4
0
Unknown
22 (5.6)
Breast cancer
318 (80.7)
Non-small cell lung cancer
14 (3.6)
Ovarian cancer
14 (3.6)
Hormone refractory prostate cancer
18 (4.6)
Nonhormone refractory prostate cancer
6 (1.5)
Gastric cancer
14 (3.5)
Head and neck cancer
10 (2.4)
The percentage is calculated out of the 394, the total number of patients in the study’s cohort for sex, age, ECOG status, and cancer type.